Compare KMX & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMX | IMVT |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.0B |
| IPO Year | 2002 | 2019 |
| Metric | KMX | IMVT |
|---|---|---|
| Price | $42.52 | $23.85 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 9 |
| Target Price | ★ $40.08 | $30.78 |
| AVG Volume (30 Days) | ★ 2.9M | 916.9K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.29 | N/A |
| EPS | ★ 2.46 | N/A |
| Revenue | ★ $26,353,420,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.73 | N/A |
| P/E Ratio | $17.21 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.40 | $12.72 |
| 52 Week High | $82.79 | $29.25 |
| Indicator | KMX | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 48.62 | 34.33 |
| Support Level | $39.57 | $21.74 |
| Resistance Level | $42.64 | $24.63 |
| Average True Range (ATR) | 1.60 | 1.07 |
| MACD | 0.06 | -0.31 |
| Stochastic Oscillator | 72.47 | 9.05 |
CarMax sells, finances, and services used and new cars through a chain of over 250 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales were 83% of fiscal 2025 revenue and wholesale about 17%, with the remaining portion composed of extended service plans and repair. In fiscal 2025, the company retailed and wholesaled 789,050 and 544,312 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the US but still estimates that it had only about 3.7% US market share of vehicles 0-10 years old in calendar 2024. It seeks over 5% share. CarMax is based in Richmond, Virginia.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.